Silver Oak Securities Incorporated increased its stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report) by 60,125.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,409 shares of the company’s stock after acquiring an additional 2,405 shares during the period. Silver Oak Securities Incorporated’s holdings in BeOne Medicines were worth $882,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in the stock. Mather Group LLC. raised its holdings in BeOne Medicines by 192.0% during the third quarter. Mather Group LLC. now owns 73 shares of the company’s stock worth $27,000 after purchasing an additional 48 shares in the last quarter. GAMMA Investing LLC lifted its position in BeOne Medicines by 39.5% in the third quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock worth $44,000 after purchasing an additional 34 shares during the period. Parallel Advisors LLC boosted its stake in BeOne Medicines by 24.0% during the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after purchasing an additional 68 shares in the last quarter. Provenance Wealth Advisors LLC bought a new position in BeOne Medicines during the 3rd quarter valued at $106,000. Finally, Knights of Columbus Asset Advisors LLC bought a new position in BeOne Medicines during the 3rd quarter valued at $106,000. Institutional investors and hedge funds own 48.55% of the company’s stock.
BeOne Medicines Trading Up 0.5%
BeOne Medicines stock opened at $413.26 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 3.55. The firm has a market cap of $45.37 billion, a price-to-earnings ratio of 52.51 and a beta of 0.63. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $424.73. The firm’s 50 day moving average price is $371.47 and its two-hundred day moving average price is $328.96.
Analyst Upgrades and Downgrades
ONC has been the topic of several research analyst reports. China Intl Cap started coverage on BeOne Medicines in a research report on Friday, November 6th. They set a “strong-buy” rating on the stock. Wolfe Research restated an “outperform” rating and issued a $370.00 price objective on shares of BeOne Medicines in a report on Monday, August 10th. Citizens Jmp raised their target price on BeOne Medicines from $405.00 to $463.00 and gave the company a “market outperform” rating in a research note on Friday, November 6th. JPMorgan Chase & Co. raised their target price on BeOne Medicines from $425.00 to $445.00 and gave the company an “overweight” rating in a research note on Thursday, October 1st. Finally, Weiss Ratings raised BeOne Medicines from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $440.56.
Get Our Latest Stock Analysis on BeOne Medicines
Insider Buying and Selling
In other news, COO Xiaobin Wu sold 280 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total transaction of $106,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Titus B. Ball sold 1,559 shares of the stock in a transaction on Friday, November 6th. The shares were sold at an average price of $405.57, for a total value of $632,283.63. Following the completion of the transaction, the insider owned 880 shares of the company’s stock, valued at $356,901.60. This trade represents a 63.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 135,571 shares of company stock valued at $48,487,792. Insiders own 6.19% of the company’s stock.
BeOne Medicines Company Profile
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
See Also
- Five stocks we like better than BeOne Medicines
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report).
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
